Milliman’s Post

View organization page for Milliman, graphic

74,789 followers

🩺The 2025 Medicare bid cycle was challenging for all stakeholders, let’s dive in with Milliman’s actuarial experts to discuss how this impacts life sciences organizations. 💡 Join Milliman’s Medicare Part D experts as they discuss lessons from this year’s bid cycle and provide critical insights and answer pressing questions including: •New formulary strategies •Disruptions to plan membership •Changes in plan benefits •Impact of the new Part D design on patients' out-of-pocket costs   Speakers: Matthew Hayes, Ryan Swenson, Peter Heinen, FSA, MAAA Moderator: Maggie Alston Don't miss out on this opportunity to stay ahead of the curve! Register now! #Milliman #MillimanLifeSciencesLive #Medicare

2025 Medicare Bid Cycle: Life Sciences Insights

2025 Medicare Bid Cycle: Life Sciences Insights

www.linkedin.com

How did the predictions of the National Average Bid Amount line up with what Milliman expected? And what if anything can be gleaned from the regional low-income benchmarks, which in some states show substantial reductions?

Like
Reply

Do you expect payers to restrict pharmacy networks?

Like
Reply
Peter Park

Commercial Rotation Development Program at Genentech

2mo

What other levers and strategies outside of UM do you see payers implementing to manage costs?

Like
Reply
Sally Schaeffer

Client Engagement Leader ◊ Marketing & Communications Strategist ◊ Facilitating Advocacy & Community Education

2mo

What percentage of members do you think will participate in the M3P program?

Like
Reply

Do you expect manufacturers will delay drug launches to game IRA drug negotiations?

Like
Reply

What is the IRA impact to PBM in your view ?

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics